Latin America Gene Expression Market Growth & Trends

The Latin America gene expression market size is expected to reach USD 578.3 million by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.6% from 2020 to 2027. High investment in alternative approaches for drug discovery and an increased number of projects involving genetic studies are expected to drive demand.

The region is characterized by fragmented healthcare and a high rate of poverty as well as disparities to access to standard care for cancer and other complex disorders. In this region, consumers from public settings are unable to afford targeted therapies. The number of facilities providing genomic platforms is limited in the region. These factors have resulted in the low revenue share of the Latin America market in the global market for gene expression.

However, researchers and healthcare providers are pursuing training for the use of genomic platforms and constantly participating in genomic projects. Currently, a medical practice based on precision medicine is still a challenge and limited to private settings in Latin America. A rise in the number of research studies pertaining to gene expression, genomic medicine, and personalized medicine in the LATAM region is expected to drive the market.

The Brazilian Initiative on Precision Medicine (BIPMed) is the first Latin American and Brazilian beacon, which is a genetic mutation sharing platform established by the Global Alliance for Genomics and Health (GA4GH). BIPMed encourages propagation and guidance in areas of computational ecology, personalized medicine, molecular hereditary, and others. This initiative plays an important role in the development of precision medicine in Latin America, thereby enabling significant advancements in healthcare and research in this region.

Latin America Gene Expression Market Report Highlights

  • cDNA synthesis and conversion accounted for the largest revenue share in 2019. The introduction of systems that provide direct library synthesis eliminating the need for prior steps is expected to increase the revenue share of the segment
  • Kits and reagents generated the largest product revenue in 2019 owing to the commercial availability of a broad range of kits and reagents to support biological discoveries and advancements
  • Moreover, the introduction of enhanced kits and reagents that support better workflow, also contributes to segment growth
  • Availability of products with higher efficiency, better adoption to specific research need, and decline in prices of associated techniques is projected to drive growth in the coming years
  • High-Plex capacity is expected to witness the fastest CAGR from 2020 to 2027. The segment also accounted for the largest revenue share owing to high adoption in clinical and drug discovery uses
  • Increased demand for advanced diagnostic solutions is expected to fuel the growth of the clinical diagnostics segment
  • RNA expression dominated the technique segment. Technological advances in RNA expression tools and techniques coupled with the availability of a range of products to meet different research needs are anticipated to increase the adoption of these techniques for gene expression analysis
  • Brazil accounted for the largest revenue generation in 2019 owing to continuous developments in genomic and healthcare-related research in the country
  • Competition in the market is high due to the presence of a substantial number of well-established companies and small- to mid-sized entities
  • Key players are manufacturing and commercializing products to cater to various requirements in gene expression. To maintain a significant share in the market, players have implemented several business strategies including the expansion of distribution network, product portfolio, and increase in manufacturing capacity through mergers and collaborations